Call for cervical cancer vaccine every day, do you understand the advantage of 9 price?

2020-09-17 22:28:19 movie 2552℃

Since the 9-valent HPV vaccine can be vaccinated in China, this type of vaccine has always been a popular choice for everyone before vaccination. I often receive such questions when I consult online.

Although everyone says that the 9-valent vaccine is good, the good news is that most people are probably at a loss. Today, let’s talk about the advantages of the 9-valent HPV vaccine in detail. What does the "price" of

9-valent HPV vaccine mean? There are hundreds of subtypes of

HPV, and HPV vaccines currently on the market at home and abroad include 2, 4, and 9 valences. The valence of the vaccine represents the number of HPV subtypes to prevent. The more valence, the more HPV subtypes are prevented, and the higher the preventive effect in theory. The HPV subtypes that the

9-valent vaccine prevents include: 6, 11, 16, 18, 31, 33, 45, 52 and 58, which can prevent 90% of cervical cancer, 85% of vaginal cancer, 80% of high-grade cervical lesions, and 50% of low Grade lesions, 90% condyloma acuminatum, 95% anal cancer .

Compared with the effect of 2-valent vaccine against 70% of cervical cancer, 4-valent vaccine against 70% of cervical cancer, and 90% of genital warts, there is no doubt that 9-valent is the most versatile player in the world. In theory, prevention The effect is more perfect.

theory is always good, what are the facts?

Since the launch of the HPV vaccine, various studies have emerged one after another. Everyone wants to know whether this vaccine is useful.

In September 2017, Warner K Huh and others published a related study on the comparison of HPV 9-valent vaccine and 4-valent vaccine on Lancet. They mainly analyzed 4-valent HPV vaccine (HPV6, 11, 16 and 18) and 9-valent HPV vaccine (HPV6). , 11, 16, 18, 31, 33, 45, 52, and 58) vaccines are effective in preventing infections related to HPV 31, 33, 45, 52, and 58, and the titers of HPV 6, 11, 16 and 18 antibody response, and The 5-year follow-up of the population vaccinated with HPV9-valent vaccine was studied.

This study is a randomized, double-blind study conducted in multiple research centers in many countries. The subjects of the study were young women aged 16-26 who were vaccinated against HPV between September 26, 2007 and December 18, 2009. The effect, immunogenicity and safety of 9-valent HPV. Recruited 14,215 healthy women aged 16-26 with no previous abnormal cervical cytology, no abnormal cervical biopsy, and no more than 4 sexual partners. They were randomly divided into groups of 1:1 and received three intramuscular injections within 6 months. Vaccination with 9-valent HPV vaccine or 4-valent HPV vaccine. Finally, cervical tissue samples were taken for pathological diagnosis, HPV DNA was detected, and serum antibodies were detected by immunofluorescence. The following indicators were compared:

and HPV31, 33, 45, 52 and 58 related high-grade cervical lesions (cervical epithelium) Neoplastic lesions (CIN) grade 2/3, cervical adenocarcinoma in situ, cervical invasive carcinoma), vulvar lesions (vulvar intraepithelial neoplasia (VIN) grade 2/3, vulvar cancer ) and vaginal lesions (vagina) The incidence of intraepithelial neoplasia (VAIN grade 2/3, vaginal cancer).
Geometric mean titer (GMT) titer of anti-HPV6, 11, 16 and 18 antibodies. The

researchers found that among these populations, the incidence of high-grade cervical, vulvar, and vaginal lesions related to HPV 31, 33, 45, 52, and 58 in the 9-valent HPV vaccine group was on average per 10,000 people per year. 0.5 case, in the 4-valent HPV vaccine group, 19.0 cases per 10,000 people per year on average, and the effectiveness accounted for 97.4%. In the 9-valent HPV group compared with the 4-valent HPV group, the geometric titers of HPV 6, 11, 16, and 18 remained at a high level from 1 month to 3 years after vaccination. There was no clinical statistical difference in serious adverse reactions between the two groups. The final conclusions of the study are as follows:

9-valent HPV vaccine can prevent infections, cervical cytology abnormalities, high-grade lesions and cervical cancer related to HPV 31, 33, 45, 52 and 58.
9-valent HPV vaccine and 4-valent HPV vaccine are similar in immunogenicity to HPV6, 11, 16 and 18. The vaccine is effective for up to 6 years. z38The z
9-valent HPV vaccine can provide wider coverage and prevent 90% of cervical cancers worldwide. The advantages of

are obvious. Who is suitable for

9-valent HPV vaccine?

At present, the population of 9-valent vaccines in China is limited to women between 9 and 26 years old. In the United States or some other countries, men or women older than 9 years old can be vaccinated, and there is no upper age limit. Why is it so stipulated?

Because there are many data on the safety and effectiveness of the 9-valent vaccine for women between 9-26 years old, and the 9-valent vaccine has not been tested in China before it is launched in China, it is a conditional listing and has not been approved. Vaccination for women over 26 years old. In fact, in addition to considering safety issues, the protective power of vaccines is also one of them. In terms of the current effects of bivalent and quadrivalent vaccines, the older the age, the protective effect after vaccination will also decrease. Therefore, in the absence of sex Before life, vaccination within the prescribed age range will be more cost-effective.

Of course, women who are over the prescribed age after having sex can also choose to vaccinate. Go to countries where there is no age limit to vaccinate. Please vaccinate as soon as possible within the age range.

finally needs to remind everyone that the protection rate after vaccination is not 100%. Although the 9-valent vaccine is already excellent, it still cannot replace routine cervical screening after vaccination, and it is impossible to prevent all HPV infections. No matter what type of HPV vaccine is vaccinated, it is still recommended to start regular cervical screening from 21 years old after having sex.